Body sculpting or contouring — or procedures in which excess body fat from specific areas is removed to achieve a patient’s desired appearance — have become increasingly popular cosmetic procedures sought by patients. Data gathered by Statista showed there were over 600,000 body sculpting procedures performed in the U.S. in 2018 alone. Procedures to remove fat from specific areas can involve nonsurgical freezing or heating, surgical removal or the injection of an acid into the desired area.

One UCI startup is prepared to shock the industry with a new minimally invasive approach to achieve precision body contouring results with little more than a saline solution and an electric current.

IT’S ELECTRIC
After receiving his Ph.D. in Biomedical Engineering from UC Irvine’s (UCI) Henry Samueli School of Engineering, Joon You, Ph.D., became interested in starting companies. He co-founded the optical imaging company that would become Modulim — a UCI startup — and has co-founded several startups since.

One such project had You working with longtime collaborator Dr. Brian Wong, a facial plastic surgeon at the UCI Medical Center and faculty at the School of Medicine and the School of Engineering, developing a technology from Wong’s lab. Dr. Wong’s research centered around using electrochemistry to alter living tissues.

The use of electrochemistry to alter living tissue was discovered by accident by Wong and his post-doctoral fellow at the time, Sergio Diaz-Valdez. Through what can only be described as a happy accident caused by a mix-up when setting up the circuitry, the procedure did not produce heat through radiofrequency energy but still happened to elicit the same desired result.

“It was a mystery,” said You, “But the only explanation was electrochemistry, because of the low voltage and small current.”

The potential market for a device that reshapes cartilage through electrochemistry — or a chemical reaction created by electricity — was relatively small, so the team looked elsewhere across many potential applications in medicine.

Because the technology could be easily tuned to dissolve fat, the team believed it could be used for body contouring procedures as an alternative to the more costly and more invasive surgical procedures.

“Originally, we were not sure if we were ready to start another company, but decided to give it a try,” said You. “We were then able to get proof of concept funding from Beall Applied Innovation and that really helped us get to our first animal study, which can be very expensive and difficult to get funding for at that stage.”

With help from the Proof of Product (POP) Grant-funded animal study, eLysis demonstrated that the technology can achieve precision body contouring results by giving pigs the appearance of six-pack abs.

With that, eLysis Inc. was established and co-founded by You, chief technology officer and interim CEO; Wong; Michael Hill, Ph.D., a professor of Chemistry at Occidental College; and Dr. Steve Yoelin, an ophthalmologist and developer of Latisse, the pharmaceutical treatment for growing eyelashes.

BREAK IT DOWN FOR ME
The main technology behind eLysis is called electrochemical lysis of fat (ELF), which breaks down fat cells with electric currents. As fat is not electrically active, saline solution with lidocaine is injected into the target fat layer, followed by the specialized electrode needles of the ELF device, to which a small electrical potential is applied. The electrochemical reaction breaks down the fat cells at a molecular level and changes the relative pH of the area, which causes immediate and sustained fat cell breakdown over a two-to-three-month period.

While there are other fat-removal procedures such as liposuction or freezing that are used for larger areas of the body, the eLysis’ system is far more precise and would ideally be used in more specific area, like on the face or to contour the stomach area to create the appearance of six-pack abs.

“If you’re a surgeon — or dermatologist, especially — and want to be able to do refined or touch-up treatment, this technology is much better than any other procedure currently available,” said You.

What’s more, eLysis is confident that their ELF system would require a significantly smaller investment for users than other fat-reduction and body contouring systems on the market today, which they plan to market to plastic surgeons, dermatologists and medical spas.

Joon You, Ph.D., eLysis chief technology officer and interim CEO, works toward getting the startup to their first in-human feasibility test.
Joon You, Ph.D., eLysis chief technology officer and interim CEO, works toward getting the startup to their first in-human feasibility test.

LOOKING GOOD
To date, the eLysis team has secured over $400,000 in nondilutive funding, which has gone a long way in getting early animal data and moving their technology closer to commercial viability. Additionally, the eLysis team has a portfolio of intellectual properties crucial to their proprietary technology’s success, including those developed at UCI. To secure exclusive rights to use those patents, eLysis has worked with the Research Translation Group at UCI Beall Applied Innovation to establish licensing agreements.

And in 2019, after placing first in the Tech Surge and Life Science tracks of the New Venture Competition, eLysis joined the Wayfinder program. While in the incubator program, the team has received valuable advice on marketing and the FDA approval process from Innovation Advisors.

More recently, eLysis received a $10,000 grant from The Nicholas Endowment, an organization that supports the arts and sciences in Southern California, which they used to further develop their technology.

MAKING IT HAPPEN
The startup is currently reaching out to potential strategic partners, expanding their expertise on electrochemistry and seeking additional investment.

“This is not like a software company,” said You. “We have to do a lot of chemistry to make sure we know what we’re doing before we inject it into humans or animals, so it is far more expensive to achieve certain milestones.”

The next round of funding eLysis raises will go toward developing a clinical prototype and initiating their first in-human feasibility test — a crucial step toward the FDA 510(k) approval process, human trials and eventually product launch.

Learn more about eLysis.

Main illustration: Elisa Le
Photography: Julie Kennedy